Home › Companies › ELTX

Elicio Therapeutics

ELTX Lead: Phase 2 ★ Read the deep dive → 1 Biotech Distilled article ↓

Most recent annual filing: 2026-03-12

Pipeline (6 active programs)

Undisclosed indication Preclinical

ELI-008

Peptide Target: TP53

Undisclosed indication Preclinical

ELI-004

Nucleic Acid

Sarcoma Preclinical intratumoral

Technology platforms

AMP · MIT

Amphiphile (AMP) technology — lymph node-targeted delivery platform using albumin hitchhiking to deliver peptides, proteins, nucleic acids and small molecules to lymph nodes; applications in cancer immunotherapy (mKRAS, BRAF, TP53 neoantigen vaccines), CAR-T and TCR-T cell therapy enhancement, prophylactic vaccines, and autoimmune disease

Targets: KRAS, BRAF, TP53

Biotech Distilled coverage (1)

2026-06-12 Elicio Therapeutics (ELTX) - Scientific Deep Dive for ELI-002 7P and the AMP Pipeline

Articles open on Substack. Some deep dives are subscriber-only.

Pipeline (6 active programs)

ELI-002 7P

ELI-002 2P

ELI-007

ELI-008

ELI-004

Technology platforms

AMP · MIT

Biotech Distilled coverage (1)